10 May 2022 Augustine Therapeutics appoints Gerhard Koenig as Chairman of the Board, forms Clinical Advisory Board, and broadens therapeutic indications Member news
10 May 2022 UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis Member news
09 May 2022 Quality by Design (QbD) becomes QbD Group, consolidating its offerings to support the development of innovative life science products, “from idea to patient” Member news
09 May 2022 Oxurion announces top-line results from Part A of Phase 2 INTEGRAL trial evaluating THR-687 for treatment of diabetic macular edema (DME) Member news
06 May 2022 Ziphius Vaccines and Ghent University publish promising data from self-amplifying RNA platform in Molecular Therapy Member news
05 May 2022 argenx announces positive Phase 3 data from ADVANCE trial of VYVGART® (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia Member news
05 May 2022 The European Spatial Biology Center (ESBC): State-of-the-art spatial biology services enabled at scale in Leuven Member news
04 May 2022 New study led by Memorial Sloan Kettering Cancer Center (NY, US) shows Idylla™ GeneFusion Assay enables more rapid screening of targetable fusions compared to routine methods Member news
03 May 2022 reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
